Public skeptical of research if tied to a company

When it comes to research warning us about the latest health risks or touting the latest cure, a new Michigan State University study indicates that many people won't trust the findings when an industry partner, even with a good reputation, is involved. The study, published in PLoS One, could present scientists with the additional dilemma of finding alternative funding sources, especially during a time when federal funding may be scarce, that won't jeopardize the perceived integrity of their research.

"People have a hard time seeing research related to health risks as legitimate if done with a corporate partner," said John Besley, lead author and an associate professor who studies the public's perception of science. "This initial study was meant to understand the scope of the problem. Our long-term goal though is to develop a set of principles so that quality research that's tied to a company will be better perceived by the public."

Using research about genetically modified foods and trans fats, study participants were randomly assigned to evaluate one of 15 different partnership scenarios that included varying combinations of scientists from a university, a government agency, a non-governmental organization and a large food company.

The results clearly showed that the public's skepticism increased substantially when a food company was in the mix. In fact, in one portion of the study, 77 percent of participants who were asked to describe their views about this type of partnership scenario had something negative to say about it and questioned whether it could produce good results.

When the partnership didn't include a corporate partner, only 28 percent of participants said something negative.

The research also indicated that this unfavorable perception didn't change much, even if other entities, such as the Centers for Disease Control and Prevention, were included as additional partners.

"This tells us that you can't just add organizations from various sectors and hope people will expect these partners to balance each other out," Besley said.

According to Besley, scientists often spend a good portion of their time trying to find the resources to pay for things like equipment, data collection and staff for their research projects. And as federal and state funding continues to hang in the balance, along with ever-increasing competition for grant dollars, this makes looking for alternative funding sources a priority.

"Ultimately, the hope is to find some way to ensure quality research isn't rejected just because of who is involved," Besley said. "But for now, it looks like it may take a lot of work by scientists who want to use corporate resources for their studies to convince others that such ties aren't affecting the quality of their research."

Besley JC, McCright AM, Zahry NR, Elliott KC, Kaminski NE, Martin JD.
Perceived conflict of interest in health science partnerships.
PLoS One. 2017 Apr 20;12(4):e0175643. doi: 10.1371/journal.pone.0175643.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Sanofi and Regeneron announce that cemiplimab (REG…

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemipli...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]